Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer.
Kobayashi S, Ueno M, Ikeda M, Ozaka M, Sano Y, Hirotani A, Tozuka Y, Fukushima T, Tezuka S, Moriya S, Umemoto K, Watanabe K, Sasaki M, Hashimoto Y, Imaoka H, Ohno I, Mitsunaga S, Yamada I, Sasaki T, Sasahira N, Morimoto M. Kobayashi S, et al. Among authors: imaoka h. Pancreas. 2020 Feb;49(2):187-192. doi: 10.1097/MPA.0000000000001484. Pancreas. 2020. PMID: 32011536
Can long-term follow-up strategies be determined using a nomogram-based prediction model of malignancy among intraductal papillary mucinous neoplasms of the pancreas?
Hijioka S, Shimizu Y, Mizuno N, Hara K, Imaoka H, Mekky MA, Bhatia V, Nagashio Y, Hasegawa T, Shinagawa A, Sekine M, Tajika M, Tanaka T, Ishihara M, Niwa Y, Yamao K. Hijioka S, et al. Among authors: imaoka h. Pancreas. 2014 Apr;43(3):367-72. doi: 10.1097/MPA.0000000000000033. Pancreas. 2014. PMID: 24622065
Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.
Yamaue H, Shimizu A, Hagiwara Y, Sho M, Yanagimoto H, Nakamori S, Ueno H, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Yokota I, Ohashi Y, Shirasaka T. Yamaue H, et al. Among authors: imaoka h. Cancer Chemother Pharmacol. 2017 Apr;79(4):813-823. doi: 10.1007/s00280-017-3250-8. Epub 2017 Mar 1. Cancer Chemother Pharmacol. 2017. PMID: 28251282 Clinical Trial.
Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.
Shibuya H, Hijioka S, Sakamoto Y, Ito T, Ueda K, Komoto I, Kobayashi N, Kudo A, Yasuda H, Miyake H, Arita J, Kiritani S, Ikeda M, Imaoka H, Ueno M, Kobayashi S, Furuta M, Nagashio Y, Murohisa G, Aoki T, Matsumoto S, Motoya M, Azemoto N, Itakura J, Horiguchi S, Yogi T, Kawagoe T, Miyaoka Y, Imamura F, Senju M, Arioka H, Hara K, Imamura M, Okusaka T. Shibuya H, et al. Among authors: imaoka h. Cancer Chemother Pharmacol. 2018 Oct;82(4):661-668. doi: 10.1007/s00280-018-3656-y. Epub 2018 Jul 27. Cancer Chemother Pharmacol. 2018. PMID: 30054710
211 results